Moderna Cancer Vaccine Trial Success Fuels 177% Stock Surge
Translated from Korean, summarized and contextualized by DistantNews.
At a glance
News
Sources not specified
New plan
- Moderna announced its personalized mRNA cancer vaccine, developed with Merck, met its primary endpoint in a Phase 3 trial for high-risk melanoma patients.
- The vaccine, known as intisemera autogene (V940/mRNA-4157), targets up to 34 neoantigens specific to each patient's tumor, aiming to prevent cancer recurrence and metastasis.
- This success marks the first time a personalized cancer therapy has shown positive results in a large-scale Phase 3 clinical trial, leading to a significant surge in Moderna's stock price.
Moderna's stock soared by 177% in a single day following the announcement of successful Phase 3 clinical trials for its personalized cancer vaccine. The vaccine, developed in collaboration with Merck, targets high-risk melanoma patients and aims to prevent cancer recurrence and metastasis.
The personalized mRNA vaccine, codenamed V940 and also known as intisemera autogene (mRNA-4157), is designed to target up to 34 neoantigens found in an individual patient's tumor. This tailored approach leverages mRNA technology, similar to that used in COVID-19 vaccines, to train the immune system to fight cancer.
This breakthrough is particularly significant as it represents the first time a personalized cancer therapy has achieved positive outcomes in a large-scale Phase 3 clinical trial. The trial involved over 1,100 patients who had undergone surgery to remove melanoma. The positive results have also boosted related biotechnology stocks in the South Korean market.
DistantNews Editorial
Originally published by Dong-A Ilbo in Korean. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.
More Stories
From Our Blog
What Gets Lost (and Found) When News Is Translated
The Critical Role of Diaspora Media in Global News
What Travellers Should Know About Countries with Restricted Press
A Digital Nomad's Guide to Following Local News
How the Same Story Looks Different in Different Countries
